PRELUDE THERAPEUTICS INC Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
PRELUDE THERAPEUTICS INC (PRLD) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of -$4.68 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-08-11
- PRELUDE THERAPEUTICS INC increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-06-30 was $1.92M, a 2.73% increase year-over-year.
- PRELUDE THERAPEUTICS INC increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was -$6.60M.
- PRELUDE THERAPEUTICS INC increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-12-31 was -$515.00K, a 132.87% decline year-over-year.
- PRELUDE THERAPEUTICS INC increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-09-30 was -$367.00K, a 117.55% decline year-over-year.
- PRELUDE THERAPEUTICS INC increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2025 was -$2.98M.
- PRELUDE THERAPEUTICS INC increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2024 was -$808.00K, a 132.04% decline from fiscal 2023.
- PRELUDE THERAPEUTICS INC increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2023 was $2.52M, a 63.09% decline from fiscal 2022.
- PRELUDE THERAPEUTICS INC increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2022 was $6.83M, a 177.43% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$4.68M 10-Q · filed 2026-08-11 | -$5.20M derived: sum of 3 quarters · filed 2026-08-11 | -$5.56M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$6.60M 10-Q · filed 2026-05-12 | -$7.12M derived: sum of 2 quarters · filed 2026-05-12 | -$7.48M derived: sum of 3 quarters · filed 2026-05-12 | -$5.61M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$515.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | -$882.00K derived: sum of 2 quarters · filed 2026-03-10 | $988.00K derived: sum of 3 quarters · filed 2026-08-11 | -$2.98M 10-K · filed 2026-03-10 |
| 2025-09-30 | -$367.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $1.50M derived: sum of 2 quarters · filed 2026-08-11 | -$2.46M 10-Q · filed 2025-11-12 | -$898.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $1.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$2.10M 10-Q · filed 2026-08-11 | -$531.00K derived: sum of 3 quarters · filed 2026-08-11 | $1.56M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$3.97M 10-Q · filed 2026-05-12 | -$2.40M derived: sum of 2 quarters · filed 2026-05-12 | -$310.00K derived: sum of 3 quarters · filed 2026-05-12 | $916.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $1.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $3.66M derived: sum of 2 quarters · filed 2026-03-10 | $4.88M derived: sum of 3 quarters · filed 2026-03-10 | -$808.00K 10-K · filed 2026-03-10 |
| 2024-09-30 | $2.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $3.32M derived: sum of 2 quarters · filed 2025-11-12 | -$2.38M 10-Q · filed 2025-11-12 | $2.02M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $1.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$4.47M 10-Q · filed 2025-08-14 | -$71.00K derived: sum of 3 quarters · filed 2025-08-14 | $2.55M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$5.69M 10-Q · filed 2025-05-06 | -$1.30M derived: sum of 2 quarters · filed 2025-05-06 | $1.32M derived: sum of 3 quarters · filed 2025-05-06 | -$1.27M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $4.39M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $7.01M derived: sum of 2 quarters · filed 2025-03-10 | $4.42M derived: sum of 3 quarters · filed 2025-03-10 | $2.52M 10-K · filed 2025-03-10 |
| 2023-09-30 | $2.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $30.00K derived: sum of 2 quarters · filed 2024-11-06 | -$1.87M 10-Q · filed 2024-11-06 | $1.30M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | -$2.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$4.49M 10-Q · filed 2024-08-12 | -$1.32M derived: sum of 3 quarters · filed 2024-08-12 | $1.84M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | -$1.90M 10-Q · filed 2024-05-07 | $1.27M derived: sum of 2 quarters · filed 2024-05-07 | $4.43M derived: sum of 3 quarters · filed 2024-05-07 | $5.33M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $3.17M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $6.34M derived: sum of 2 quarters · filed 2024-02-15 | $7.23M derived: sum of 3 quarters · filed 2024-02-15 | $6.83M 10-K · filed 2024-02-15 |
| 2022-09-30 | $3.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $4.06M derived: sum of 2 quarters · filed 2023-11-01 | $3.66M 10-Q · filed 2023-11-01 | $6.52M derived: sum of 4 quarters · filed 2023-11-01 |
| 2022-06-30 | $896.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $495.00K 10-Q · filed 2023-08-03 | $3.35M derived: sum of 3 quarters · filed 2023-08-03 | $3.81M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | -$401.00K 10-Q · filed 2023-05-08 | $2.46M derived: sum of 2 quarters · filed 2023-05-08 | $2.92M derived: sum of 3 quarters · filed 2023-05-08 | $3.43M derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | $2.86M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $3.32M derived: sum of 2 quarters · filed 2023-03-15 | $3.83M derived: sum of 3 quarters · filed 2023-03-15 | $2.46M 10-K · filed 2023-03-15 |
| 2021-09-30 | $463.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $979.00K derived: sum of 2 quarters · filed 2022-11-14 | -$393.00K 10-Q · filed 2022-11-14 | $749.00K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $516.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$856.00K 10-Q · filed 2022-08-09 | $286.00K derived: sum of 3 quarters · filed 2022-08-09 | $4.42M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | -$1.37M 10-Q · filed 2022-05-10 | -$230.00K derived: sum of 2 quarters · filed 2022-05-10 | $3.90M derived: sum of 3 quarters · filed 2022-05-10 | $4.51M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $1.14M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $5.27M derived: sum of 2 quarters · filed 2022-03-17 | $5.88M derived: sum of 3 quarters · filed 2022-03-17 | $4.61M 10-K · filed 2022-03-17 |
| 2020-09-30 | $4.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $4.74M derived: sum of 2 quarters · filed 2021-11-12 | $3.47M 10-Q · filed 2021-11-12 | $4.96M derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | $610.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$658.00K 10-Q · filed 2021-08-12 | $827.00K derived: sum of 3 quarters · filed 2021-08-12 | |
| 2020-03-31 | -$1.27M 10-Q · filed 2021-05-11 | $217.00K derived: sum of 2 quarters · filed 2021-05-11 | ||
| 2019-12-31 | $1.49M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $1.47M 10-K · filed 2021-03-16 | ||
| 2019-09-30 | -$19.00K 10-Q · filed 2020-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |